Coya Therapeutics, Inc. (COYA) Income Statement
COYA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCOYA revenue and net income
Where COYA's revenue goes
2025Each bar shows an amount and its share of revenue. COYA kept −267.1% of revenue as net income.
COYA profit margins
COYA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +123.6% | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
COYA quarterly EPS vs estimates
Coya Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.35).
COYA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $7.9M | $3.6M | $6.0M | $0 | $0 | $0 |
| Cost of revenue | $27,361 | $11.9M | $5.5M | $4.4M | $16,133 | — |
| Gross profit | $7.9M | −$8.3M | $500,679 | −$4.4M | −$16,133 | — |
| Research & development | $16.7M | $11.9M | $6.0M | $4.9M | $2.5M | $373,454 |
| Sales, general & admin | $11.4M | $8.9M | $7.8M | $4.8M | $2.3M | $668,700 |
| Total operating expenses | $28.2M | $8.9M | $8.4M | $5.4M | $4.9M | $1.0M |
| Operating income | −$20.3M | −$17.2M | −$7.9M | −$9.8M | −$4.9M | −$1.0M |
| Interest expense | — | — | — | $2.4M | $21,482 | $38,976 |
| Income before taxes | −$21.2M | −$15.6M | −$7.3M | −$12.2M | −$4.9M | −$1.1M |
| Income taxes | $3,089 | −$720,287 | $723,852 | $2.4M | −$21,482 | −$704 |
| Net income | −$21.2M | −$14.9M | −$8.0M | −$12.2M | −$4.9M | −$1.1M |
| EBITDA | −$21.2M | −$17.2M | −$7.3M | −$9.3M | −$4.9M | $10,435 |
| EPS (diluted) | −$1.27 | −$0.98 | −$0.78 | −$0.51 | −$0.74 | — |
| Gross margin | 99.7% | −233.9% | 8.3% | — | — | — |
| Operating margin | −255.0% | −485.4% | −131.7% | — | — | — |
| Net margin | −267.1% | −418.7% | −133.1% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $243,745 | $251,147 | $4.0M | $3.6M | $163,616 | $257,884 | $1,952 | $0 | $3.4M | $126,838 | $6.0M | $0 |
| Cost of revenue | $0 | $2,807 | −$5.2M | $6,840 | $6,840 | $5.2M | $1.9M | $2.2M | $4.6M | $3.1M | $1.6M | $1.6M |
| Gross profit | $243,745 | $251,147 | $4.0M | $3.6M | $156,776 | −$5.0M | −$1.9M | −$2.2M | −$1.1M | −$3.0M | $4.4M | −$1.6M |
| Research & development | $5.0M | $4.1M | $6.7M | $2.9M | $3.66B | $5.2M | $1.9M | $2.2M | $4.6M | $3.2M | $1.8M | $1.6M |
| Sales, general & admin | $2.3M | $3.8M | $3.3M | $2.6M | $2.91B | $2.7M | $2.1M | $2.2M | $2.1M | $2.4M | $2.4M | $2.0M |
| Total operating expenses | $7.3M | $7.9M | $10.0M | $5.5M | $6.6M | $2.7M | $2.1M | $2.2M | $2.1M | $2.5M | $2.6M | $2.0M |
| Operating income | −$7.0M | −$7.6M | −$6.0M | −$1.9M | −$6.4M | −$7.7M | −$4.1M | −$4.5M | −$3.2M | −$5.5M | $1.8M | −$3.6M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $163,634 | — |
| Income before taxes | −$6.6M | −$7.2M | −$5.7M | −$2.1M | −$6.1M | −$7.3M | −$3.6M | −$4.0M | −$2.9M | −$5.1M | $2.0M | −$3.4M |
| Income taxes | — | — | $3,089 | — | — | $720.3M | −$720,287 | −$1 | — | −$36,436 | $723,852 | $46,427 |
| Net income | −$6.6M | −$7.2M | −$5.7M | −$2.1M | −$6.1M | −$7.3M | −$2.9M | −$4.0M | −$2.9M | −$5.1M | $1.3M | −$3.4M |
| EBITDA | −$6.6M | −$7.6M | −$5.7M | −$2.1M | −$6.1M | −$7.3M | −$3.6M | −$4.0M | −$2.9M | −$5.5M | $2.0M | −$3.4M |
| EPS (diluted) | −$0.28 | −$0.32 | −$0.34 | −$0.13 | −$0.36 | −$0.44 | −$0.18 | −$0.26 | −$0.19 | −$0.35 | $0.15 | −$0.34 |
| Gross margin | 100.0% | 100.0% | 100.0% | 99.8% | 95.8% | −1,921.9% | −99,154.1% | — | −33.3% | −2,374.1% | 73.2% | — |
| Operating margin | −2,891.1% | −3,042.1% | −152.3% | −53.8% | −3,920.5% | −2,976.9% | −209,031.5% | — | −94.5% | −4,322.8% | 30.2% | — |
| Net margin | −2,723.4% | −2,869.6% | −144.2% | −59.4% | −3,725.2% | −2,833.4% | −149,373.8% | — | −84.4% | −3,983.0% | 21.1% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in COYA's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
COYA financial results
In fiscal year 2025 (ended December 31, 2025), Coya Therapeutics reported revenue of $7.9 million, up 123.6% from the year before. It had a net loss of $21.2 million, a net profit margin of −267.1%. Diluted earnings per share came to −$1.27.
See the COYA stock overview for the latest quote and news, or the COYA chart for price history and technical indicators.
COYA income statement FAQ
What is Coya Therapeutics's annual revenue?
Coya Therapeutics reported total revenue of $7.9 million for fiscal year 2025, which ended on December 31, 2025. That was up 123.6% from $3.6 million the previous year.
Is Coya Therapeutics profitable?
No. Coya Therapeutics reported a net loss of $21.2 million in fiscal 2025, a net profit margin of −267.1%; its operating margin was −255.0%.
What is Coya Therapeutics's gross margin?
Coya Therapeutics's gross margin was 99.7% in fiscal 2025: for every $100 of revenue, Coya Therapeutics kept $100 after the direct cost of its products and services.
How much does Coya Therapeutics spend on research and development?
Coya Therapeutics spent $16.7 million on research and development in fiscal 2025, 210.6% of revenue.
What are Coya Therapeutics's earnings per share?
Coya Therapeutics earned $-1.27 per diluted share in fiscal 2025, compared with $-0.98 a year earlier.
When will Coya Therapeutics report its next earnings?
Coya Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Coya Therapeutics's fiscal year end?
Coya Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 16, 2026.